JOP20220204A1 - الأجسام المضادة لـ cd19 البشرية - Google Patents

الأجسام المضادة لـ cd19 البشرية

Info

Publication number
JOP20220204A1
JOP20220204A1 JOP/2022/0204A JOP20220204A JOP20220204A1 JO P20220204 A1 JOP20220204 A1 JO P20220204A1 JO P20220204 A JOP20220204 A JO P20220204A JO P20220204 A1 JOP20220204 A1 JO P20220204A1
Authority
JO
Jordan
Prior art keywords
antibodies
human
compositions
present disclosure
methods
Prior art date
Application number
JOP/2022/0204A
Other languages
English (en)
Inventor
Barret Allan
Alison Lee Sim Budelsky
Jeffrey Streetman Boyles
Kira Vladimirovna Rubtsova
Guifeng Zhang
Songqing Na
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20220204A1 publication Critical patent/JOP20220204A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الكشف الحالي بالأجسام المضادة التي تربط CD19 البشري ("الأجسام المضادة لـ CD19 البشرية" أو "الأجسام المضادة لـ CD19 البشرية")، تركيبات تتضمن هذه الأجسام المضادة لـ CD19 البشرية، وطرق استخدام هذه الأجسام المضادة لـ CD19 البشرية.
JOP/2022/0204A 2020-02-28 2021-02-22 الأجسام المضادة لـ cd19 البشرية JOP20220204A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062983093P 2020-02-28 2020-02-28
PCT/US2021/018989 WO2021173471A1 (en) 2020-02-28 2021-02-22 Anti-human cd19 antibodies

Publications (1)

Publication Number Publication Date
JOP20220204A1 true JOP20220204A1 (ar) 2023-01-30

Family

ID=74885029

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0204A JOP20220204A1 (ar) 2020-02-28 2021-02-22 الأجسام المضادة لـ cd19 البشرية

Country Status (20)

Country Link
US (1) US11623956B2 (ar)
EP (1) EP4110815A1 (ar)
JP (1) JP7450743B2 (ar)
KR (1) KR20220132579A (ar)
CN (1) CN115151570A (ar)
AR (1) AR121370A1 (ar)
AU (1) AU2021225792A1 (ar)
BR (1) BR112022015902A2 (ar)
CA (1) CA3169155A1 (ar)
CL (1) CL2022002329A1 (ar)
CO (1) CO2022012212A2 (ar)
CR (1) CR20220421A (ar)
DO (1) DOP2022000173A (ar)
EC (1) ECSP22067275A (ar)
IL (1) IL295494A (ar)
JO (1) JOP20220204A1 (ar)
MX (1) MX2022010621A (ar)
PE (1) PE20221593A1 (ar)
TW (1) TWI790548B (ar)
WO (1) WO2021173471A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023198744A1 (en) 2022-04-13 2023-10-19 Tessa Therapeutics Ltd. Therapeutic t cell product
TW202346359A (zh) 2022-04-15 2023-12-01 美商凱維那醫療公司 用於治療自體免疫疾病之方法及組合物
WO2023240064A1 (en) 2022-06-08 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101397290B1 (ko) 2005-12-30 2014-05-21 메르크 파텐트 게엠베하 감소한 면역원성을 가지는 항-ｃｄ19 항체
PT2066349E (pt) * 2006-09-08 2012-07-02 Medimmune Llc Anticorpos anti-cd19 humanizados e respectiva utilização no tratamento de tumores, transplantação e doenças auto-imunes
US20170121379A1 (en) 2014-05-08 2017-05-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Using b-cell-targeting antigen igg fusion as tolerogenic protein therapy for treating adverse immune responses
FI3468997T3 (fi) 2016-06-08 2023-10-31 Xencor Inc Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een

Also Published As

Publication number Publication date
CO2022012212A2 (es) 2022-09-09
US20210269520A1 (en) 2021-09-02
TW202146451A (zh) 2021-12-16
CA3169155A1 (en) 2021-09-02
IL295494A (en) 2022-10-01
BR112022015902A2 (pt) 2022-10-04
CN115151570A (zh) 2022-10-04
ECSP22067275A (es) 2022-09-30
AU2021225792A1 (en) 2022-09-15
JP2023515219A (ja) 2023-04-12
MX2022010621A (es) 2022-11-30
WO2021173471A1 (en) 2021-09-02
EP4110815A1 (en) 2023-01-04
CR20220421A (es) 2022-09-23
PE20221593A1 (es) 2022-10-10
JP7450743B2 (ja) 2024-03-15
AR121370A1 (es) 2022-06-01
US11623956B2 (en) 2023-04-11
KR20220132579A (ko) 2022-09-30
CL2022002329A1 (es) 2023-04-10
DOP2022000173A (es) 2022-10-31
TWI790548B (zh) 2023-01-21

Similar Documents

Publication Publication Date Title
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
CR20220421A (es) Anticuerpos anti-cd19 humano
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX2020011828A (es) Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
MX2019012869A (es) Anticuerpos anti-sortilina y metodos para su uso.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
CR20220078A (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2021015156A (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
CR20230474A (es) Anticuerpos anti-cd19 y estructuras car-t
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
MX2021000287A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2021000280A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.